Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
abstract, ALLG, Antitrust, Australian, axatilmab, azacitidine, backbone, booking, clonal, comp, concept, CRh, digit, double, featured, gradually, Incyte, INTERCEPT, IPF, JAK, lymphocytic, macroeconomic, mid, progression, proof, robust, session, simultaneously, territory, waiting
Removed:
Designation, escalation, Hematology, optimal, Recognition, reopen, scheduled, steroid, Unregistered
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view